Dear Ms. Thambipillai:

Please refer to your Supplemental Biologics License Application (sBLA), dated October 22, 2014, received October 22, 2014, submitted under section 351(a) of the Public Health Service Act for Herceptin® (trastuzumab).

We acknowledge receipt of your amendments dated February 17; March 9 and 19; and April 2, 2015.

This Prior Approval supplemental biologics application provides for revisions to update the Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology, and Patient Counseling Information sections with the 7 month washout period recommendation. Updates were also made to the Clinical Pharmacology data, Dosage and Administration and Drug Interactions sections based on the new non-linear popPK model.

When the labeling with new pregnancy/lactation content must be submitted to FDA for approval according to the implementation plan of the Pregnancy and Lactation Labeling Rule (PLLR), we recommend that you submit contemporaneous labeling supplements for Herceptin, Kadcyla and Perjeta to provide for these updates in order to maintain consistency among these labels.

**APPROVAL & LABELING**

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is
identical to the enclosed labeling text for the package insert and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, contact Amy Tilley, Regulatory Project Manager, at 301-796-3994 or amy.tilley@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Amna Ibrahim, M.D.
Deputy Director
Division of Oncology Products 1
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE:

Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

AMNA IBRAHIM
04/23/2015